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Summary
Triple-negative breast cancer (TNBC) has a poor prognosis with limited treatment options.
Genomic analysis of TNBCs offers the opportunity to decode TNBC into biologically relevant subtypes with unique molecular targets. With further research, these findings may be translated into effective targeted therapeutic options.
Main Text
In this issue of Clinical Cancer Research, Burstein and colleagues describe the findings of a genomic analysis of triple-negative breast cancers (TNBCs) (1) . TNBC has been conventionally described as breast cancer that does not express the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), although recent studies suggest that TNBC is actually quite heterogeneous (2) and cytokines were noted in the BLIA group. The authors conclude that TNBC can be categorized as 4 subtypes based on discrete molecular markers, which then can be used to identify potentially effective targeted agents.
Research. How do we apply this data to the clinic? TNBC is a difficult to treat subtype of breast cancer, with a high propensity for systemic metastases and poor survival. Chemotherapy resistance is common, and to date, there are no effective alternative treatments. In the clinic it is clear that TNBC represents a heterogeneous subset of cancers, with markedly different natural histories and response to therapy, and that additional tumor specific information is critical to finding effective therapies. Lehmann et al previously described 6 subtypes of TNBC, and identified an indolent, androgen receptor expressing subset (2). Burstein and colleagues describe 4 subtypes, with some overlap, and were unable to reproduce Lehmann's subtype definitions.
Burstein's classification also differs from Perou's categorization defining claudin low, luminal A, luminal B, HER2 positive, and basal like subtypes (3), and from Curtis' grouping using copy number aberrations (4). These differences, which may be due in part to methodology and datasets, complicate ultimate definitions but may not be clinically relevant, as the identification of actionable targets is most important to the clinic, providing a path for directed clinical research. Indeed, these studies expand the paradigm of TNBC from a disease that has been defined by the absence of hormone or HER2 receptor expression into a heterogeneous cancer defined by the presence of specific gene products ( This work adds to efforts translating molecular markers into precise cancer therapies.
While Burstein and colleagues (1) have identified several gene products for different TNBC subtypes, there is significant genetic diversity within these subtypes. A prior study showed that TNBC has a high mutation rate, leading to the acquisition of various point mutations with resulting clonal diversity (7). Therefore, several genomic alterations may be responsible for a tumor's growth, increasing the difficulty of transforming a molecular marker into an effective therapy. A single mutation may exist in only a portion of the tumor, and this may change under the pressure of treatment. This heterogeneity within a tumor makes combination therapy appealing, but also highly challenging. Molecular evolution occurs as cancer progresses, so resistance may develop to targets identified on a primary tumor, or new mutations may appear in a metastatic lesion. Essentially all of the biopsy specimens in Burstein's study were from primary tumors, hence it is possible that the molecular targets described may vary or have additional complexity in the metastatic setting. (12) . These large collaborations are essential given the focus on smaller subsets of disease and will enable a new approach to the treatment of both early and late stage disease.
The current study together with previous work, illustrate that TNBC is more complex than a subset of breast cancer not expressing ER, PR and HER2. However, this study also highlights the extent of entropy in the genomic landscape of breast cancer. With ongoing research efforts, we will one day be able to translate these molecular targets into effective personalized therapies for TNBC. 
